 |
Identifying Risk for Rheumatoid Arthritis Progression: The Role of Early Biologic Therapy CME Author Information and Disclosures Release Date: January 31, 2008; Valid for credit through January 31, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Use clinical, radiologic, functional, and quality-of-life measures to define risk for disease progression and identify patients who have inadequate response to initial therapy
- Integrate physician and patient dialogue into rheumatoid arthritis
(RA) treatment strategies to assess treatment effectiveness and prepare for a switch in therapeutic regimen
- Discuss alternative therapies for RA, including novel biologic therapies, with a variety of mechanisms of action to improve patient outcomes
Authors and Disclosures Michael H. Weisman, MD
Disclosure: Michael H.
Weisman, MD has disclosed that he has received grants for research from Amgen, Centocor, Bio-Rad, Genentech, Human Genome Sciences, UCB, Aspreva, Bristol-Myers Squibb, Wyeth, Abbott, PDL, BioPharma, and XDX, Inc. Dr. Weisman has also disclosed that he has served as an advisor or consultant to, and as a data-safety monitoring board member of, Genentech, Centocor, Lilly, Biogen, Amgen/Wyeth, Human Genome Sciences, Elan, Array, Abbott, TargeGen, TAP, Ortelius, Rigel, and Merck &
Co., Inc. Helen Fosam, PhD
Disclosure: Helen Fosam, PhD, has disclosed no relevant financial relationships. Jennifer Brown, PhD
Disclosure: Jennifer Brown, PhD, has disclosed that she was an employee of Roche within the last 12 months. Mark P. Bowes, PhD
Mark P. Bowes, PhD, has disclosed no
relevant financial relationships. |
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the University of Kentucky College of Medicine. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
University of Kentucky designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
